Maxine Gowen, Ph.D.
President and Chief Executive Officer
Dr. Gowen is the founding President and CEO of Trevena. Prior to this Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of fifteen years. As Senior Vice President for the Center of Excellence for External Drug Discovery (CEEDD), she developed an innovative new approach to externalizing drug discovery in big pharma. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in and served on the board of directors of numerous companies. Until 2002 Dr. Gowen was Vice President, Drug Discovery, Musculoskeletal Diseases at GSK, responsible for drug discovery and early development for osteoporosis, arthritis and metastatic bone disease. Dr. Gowen held a tenured academic position in the School of Pharmacology, University of Bath, UK from 1989-1992. She has authored more than 100 refereed scientific publications. Dr. Gowen graduated with a B.Sc. in biochemistry from the University of Bristol, UK, then received a Ph.D. in cell biology from the University of Sheffield, UK, and received an MBA from the Wharton School of the University of Pennsylvania. Dr. Gowen served on the board of Human Genome Sciences (HGSI) until its purchase by GSK in July 2012. She currently serves on the board of Akebia Therapeutics, Inc. (AKBA) since July 2014 and Idera Pharmaceuticals, Inc. (IDRA) since January 2016, both public biopharmaceutical companies, and on the boards of the state and national biotechnology industry associations, Life Sciences PA and BIO, respectively.
Carrie L. Bourdow
Executive Vice President and Chief Operating Officer
Ms. Bourdow joined Trevena as Senior Vice President and Chief Commercial Officer in May 2015, and was promoted to Executive Vice President and Chief Operating Officer in January 2018. Prior to joining Trevena, she was vice president of marketing, reimbursement, and operations at Cubist Pharmaceuticals, Inc., where she led launch strategy, marketing, reimbursement, and operations for five acute care hospital pharmaceuticals totaling over $1 billion in annual revenues. Before joining Cubist in 2013, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across several therapeutic areas including anti-infectives, acute heart failure, and pain. Ms. Bourdow has a B.A. degree from Hendrix College and earned her M.B.A. from Southern Illinois University. Since June 2017, she has served on the board of Nabriva Therapeutics plc., a publicly traded biopharmaceutical company.
David P. Geoghegan
Senior Vice President, Operations
Mr. Geoghegan has over 28 years of experience in a variety of operations roles including quality, manufacturing, supply chain, validation and compliance. He joined Trevena in 2015 as Vice President of Manufacturing and Pharmaceutical Technology, and became Senior Vice President, Operations, in January 2018. Mr. Geoghegan established and manages Trevena’s third-party supply chain for clinical and commercial supply, and is responsible for pharmaceutical process development. Prior to joining Trevena, Mr. Geoghegan served as the Executive Director, Manufacturing Quality Site Head at Endo Pharmaceuticals (formerly Auxilium) from 2014 to 2015. From 2012 to 2014, he was Vice President of Quality for Savient Pharmaceuticals. Before that, he served in roles of increasing responsibility for several other large and small biopharmaceutical companies, including Adolor, Aviron, MedImmune, and Wyeth. Mr. Geoghegan holds a degree in Mechanical Engineering from Villanova University and an M.B.A. from Northeastern University.
John M. Limongelli, Esq.
Senior Vice President, General Counsel and Chief Administrative Officer
Mr. Limongelli joined Trevena as Senior Vice President, General Counsel & Corporate Secretary in May 2014 and became Chief Administrative Officer in March 2016. Prior to joining us, he was Vice President, Associate Chief Counsel and Corporate Secretary at Cigna Corporation. From 2008 to 2011, he served as Senior Vice President, General Counsel and Secretary at Adolor Corporation, a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain and pain management products. Prior to Adolor, Mr. Limongelli held roles of increasing responsibility with Cephalon, Inc., most recently serving as Vice President, Associate General Counsel & Secretary. Mr. Limongelli began his legal career in private practice with Morgan, Lewis & Bockius, LLP, in Philadelphia; he also later served as a partner with a local Philadelphia-area firm after the sale of Adolor to Cubist Pharmaceuticals. Prior to becoming an attorney, Mr. Limongelli was a certified public accountant and he worked as an auditor with KPMG LLP and as a financial analyst with Bell Atlantic Corp. Mr. Limongelli obtained both his J.D. and M.B.A. with honors from Temple University.
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs, and Investor Relations Officer
Dr. Violin is one Trevena’s scientific founders, and joined the company at its inception in 2008. He became Senior Vice President of Scientific Affairs in January of 2018. He has held a variety of leadership roles at Trevena, including corporate strategy, investor relations, and discovery biology. He co-led the discovery of OLINVO™ (oliceridine) Injection, and contributed to the identification and advancement of three other novel molecules to clinical development. He has authored over 45 peer-reviewed publications. Prior to joining Trevena, Dr. Violin was a post-doctoral fellow in the laboratory of Dr. Robert Lefkowitz at Duke University Medical Center, where he studied novel mechanisms of G protein-coupled receptor pharmacology. Dr. Violin holds a Ph.D. from the Department of Pharmacology at the University of California, San Diego, an M.B.A. from the Fuqua School of Business at Duke University, and a B.S. in Chemical Pharmacology from Duke University.
Copyright © Trevena, Inc.